Plus   Neg

VistaGen Says Disappointed With Phase 2 Results On Major Depressive Disorder

VistaGen Therapeutics (VTGN) announced Phase 2 results for AV-101 as an adjunctive treatment of major depressive disorder or MDD, reporting that the AV-101 treatment arm did not differentiate from placebo on the primary endpoint. AV-101 was well tolerated, with no psychotomimetic side effects or serious adverse events.

"While we are disappointed with the topline results of the study, it is possible that efficacy may have been compromised by either insufficient transport of AV-101 across the blood brain barrier or subsequent inadequate concentrations of its active metabolite, 7-Cl-KYNA, in the brain," said Shawn Singh, Chief Executive Officer of VistaGen.

VTGN is currently trading at $0.3600, down $0.71 or 66.36 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT